Log in to save to my catalogue

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenog...

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenog...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_deb621ff4dba44b3a242c7c4570c902e

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

About this item

Full title

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

Publisher

United States: John Wiley & Sons, Inc

Journal title

Molecular oncology, 2020-01, Vol.14 (1), p.54-68

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

cMet is a well‐characterized oncogene that is the target of many drugs including small molecule and biologic pathway inhibitors, and, more recently, antibody–drug conjugates (ADCs). However, the clinical benefit from cMet‐targeted therapy has been limited. We developed a novel cMet‐targeted ‘third‐generation’ ADC, TR1801‐ADC, that was optimized at...

Alternative Titles

Full title

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_deb621ff4dba44b3a242c7c4570c902e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_deb621ff4dba44b3a242c7c4570c902e

Other Identifiers

ISSN

1574-7891

E-ISSN

1878-0261

DOI

10.1002/1878-0261.12600

How to access this item